We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Large Genetic Study Identifies New Prostate Cancer Loci

By LabMedica International staff writers
Posted on 21 Sep 2014
Data obtained during a large genetic screening study have added 23 new genetic variants to the known loci linked to development of prostate cancer.

Collaborators from a number of international research institutes conducted a meta-analysis of more than 10 million single nucleotide polymorphisms (SNPs) in 43,303 prostate cancer cases and 43,737 controls from populations of European, African, Japanese, and Latino ancestry.

Results revealed 23 previously unknown loci associated with prostate cancer of which 15 variants were identified among men of European ancestry, seven were identified in multiancestry analyses, and one was associated with early-onset prostate cancer. More...
These 23 variants, in combination with known prostate cancer risk variants, explain 33% of the familial risk for this disease in European-ancestry populations.

These findings indicate that for European men assessed for the 100 common variants, the 10% at highest risk are 2.9 times more likely than the average person to develop prostate cancer, while the top 1% of men is 5.7 times more likely to develop the disease.

Contributing author Dr. Rosalind Eeles, professor of oncogenetics at the Institute of Cancer Research (London, United Kingdom), said, "Our study tells us more about the effect of the genetic hand that men are dealt on their risk of prostate cancer. We know that there are a few major genes that are rare and significantly affect prostate cancer risk, but what we are now learning is that there are many other common genetic variants that individually have only a small effect on risk, but collectively can be very important. To use the playing cards analogy again, sometimes multiple low cards can combine to form a high risk score. We can now explain a third of the inherited risk of prostate cancer, and will shortly be conducting a clinical trial to find out whether testing for genetic variants in men can successfully pick up the disease early, and help direct targeted interventions for patients."

Related Links:

The Institute of Cancer Research



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
All-in-One Molecular System
AIO M160
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.